Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2017 | Rigosertib in combination with azacitidine: a potential treatment for AML?

Shyamala Navada • 22 Jun 2017
EHA 2017
Acute Myeloid Leukemia Azacitidine Rigosertib

Shyamala Navada, MD, from Tisch Cancer Institute, New York, NY, US, talks to us about a Phase I/II trial evaluating the effectiveness of oral rigosertib in combination with azacitidine for the treatment of acute myeloid leukemia (AML) (NCT01926587). She describes the positive results of the trial, noting that the combination was found to be safe and well-tolerated and produced a high overall response rate in comparison to monotherapy, which supports their potential use for the treatment of AML in the future. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.

More from Shyamala Navada

0:43
What is the future for AML patients who cannot be treated with current therapy?
Shyamala Navada • 22 Jun 2017

Related Videos

1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
3:34
Total marrow and lymphoid irradiation plus cyclophosphamide & etoposide in poor-risk acute leukemias
Anthony Stein • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals